Table 3 Primary outcome measures in included studies
Author (year) | Treatment | Outcome: HRQoL |
|---|---|---|
Ciezki (2017) [25] | RP ± RT ± ADT | 10 yr cumulative incidence of ≥ grade3 GU and GI toxicity: 16.4% and 1.0% |
EBRT ± ADT | 10 yr cumulative incidence of ≥ grade3 GU and GI toxicity: 8.1% and 4.6% | |
Hoffman (2020) [13] | RP | EPIC: EBRT + ADT vs RP at 3yrs (higher scores indicate a better function): |
- Sexual function score: 9.1 (3.5–14.8) – MCID: 10–12 | ||
- Urinary incontinence score: 21.8 (17.1–26.6) – MCID: 6–9 | ||
- Urinary Irritative score: 1.1 (-1.6; 3.7) – MCID: 5–7 | ||
- Bowel function score: -1.6 (-4.3;1.2) – MCID: 4–6 | ||
- Hormone function score: -0.2 (-3.0; -2.6) – MCID: 4–6 | ||
SF-36: EBRT + ADT vs RP at 3yrs (higher scores indicate a better function): | ||
- Physical Function score: -4.8 (-9.0; -0.7) – MCID: 7 | ||
- Emotional Wellbeing score: -1.7 (-4.4; 1.1) – MCID: 6 | ||
- Energy/Fatigue score: -3.4 (-6.7; -0.2) – MCID: 9 | ||
EBRT + ADT | see RP | |
Tward (2020) [23] | RP ± RT ± ADT | Difference from baseline at 24–42 months: SHIM (sexual dysfunction, lower is worse): -10 AUA-SS (urinary obstruction and irritation, higher is worse):-2.6 RFAS (bowel problems, higher is worse): 1.6 |
EBRT + ADT | Difference from baseline at 24–42 months: SHIM:-10.5, AUA-SS: -0.7; RFAS: 2.0 | |
EBRT + BT + ADT | Difference from baseline at 24–42 months: SHIM:-7, AUA-SS: -1.4; RFAS: 1.7 |